Skip to main content
. Author manuscript; available in PMC: 2023 Jun 29.
Published in final edited form as: Nat Med. 2022 Mar 21;28(4):724–734. doi: 10.1038/s41591-022-01726-1

Extended Data Table 2.

Individual patient SAEs following CART-PSMA-TGFβRDN cell infusion

Subject ID Cohort CART-PSMA-TGFβRDN Cell Attribution Toxicity Grade Duration (Days) Time from Infusion to Event (Days)
Patient 2 1 Unrelated Hematuria 4 52 26
Patient 5 1 Unrelated Hip fracture 3 2 14
Patient 6 2 Definitely Cytokine release syndrome 3 3 0
Probably Encephalopathy 3 4 0
Possibly Syncope 3 1 17
Possibly Acute kidney injury 3 3 30
Patient 7 2 Definitely Cytokine release syndrome 3 3 0
Probably Hypotension 3 2 1
Patient 8 2 Unrelated Urinary tract infection 3 7 26
Patient 9 3 Definitely Cytokine release syndrome 4 9 0
Probably Hypotension 4 8 1
Probably Respiratory failure 4 28 2
Possibly Anemia 3 26 4
Possibly Disseminated intravascular coagulation 3 26 4
Probably Acute kidney injury 4 24 6
Probably Hepatic failure 3 24 6
Unrelated Sepsis 5 10 20
Patient 11 −3 Definitely Cytokine release syndrome 2 2 0
Probably Hypoxia 3 2 0
Patient 12 −3 Definitely Cytokine release syndrome 2 8 0
Patient 14 −3 Definitely Cytokine release syndrome 1 3 25
Possibly Renal and urinary disorders - other (SIADH) 3 5 26
Patient 17 −3 Possibly Hypotension 3 2 9
Possibly Upper respiratory infection 3 5 9
HHS Vulnerability Disclosure